Regulatory T Cells and IL-10 Independently Counterregulate Cytotoxic T Lymphocyte Responses Induced by Transcutaneous Immunization

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Stein, Pamela ^a   Weber, Michael ^a   Prüfer, Steve ^a   Schmid, Beate ^a   Schmitt, Edgar ^a   Probst, Hans Christian ^a   Waisman, Ari ^a   Langguth, Peter ^b   Schild, Hansjörg ^a   Radsak, Markus P ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 10 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; TOLL LIKE RECEPTOR 7; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; SIGNAL PEPTIDE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T CELL DEPLETION; TRANSCUTANEOUS IMMUNIZATION; ANIMAL; C57BL MOUSE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; SKIN;

MUS; MUS MUSCULUS;

AMINOQUINOLINES; ANIMALS; B-LYMPHOCYTES; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; IMMUNE TOLERANCE; IMMUNIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SKIN; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84860583088     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027911     Document Type: Article

References (37)

1. Partidos CD, Beignon A-S, Briand J-P, Muller S, (2004) Modulation of immune responses with transcutaneously deliverable adjuvants. Vaccine 22: 2385-2390 doi:10.1016/j.vaccine.2003.11.063.
2. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, et al.(2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3: 196-200 doi:10.1038/ni758.
3. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, et al.(1992) Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 52: 3528-3533.
4. Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, Reiter MJ, et al.(1995) Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 15: 537-545.
5. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA, (1994) Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol 55: 234-240.
6. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, et al.(1995) Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 58: 365-372.
7. Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, et al.(1993) Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 53: 5176-5180.
8. Palamara F, Meindl S, Holcmann M, Lührs P, Stingl G, et al.(2004) Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 173: 3051-3061.
9. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP, (2005) Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174: 2476-2480.
10. Warger T, Rechtsteiner G, Schmid B, Osterloh P, Schild H, et al.(2007) Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin Rev Allergy Immunol 32: 57-66.
11. Itoh T, Celis E, (2005) Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 28: 430-437.
12. Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, et al.(2008) Tumor immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol 180: 1991-1998.
13. Stein P, Rechtsteiner G, Warger T, Bopp T, Fuhr T, et al.(2011) UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin. J Investig Dermatol 131: 211-219 doi:10.1038/jid.2010.254.
14. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, et al.(2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: 823-832.
15. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, et al.(2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201: 1591-1602 doi:10.1084/jem.20042167.
16. Hawrylowicz CM, O'garra A, (2005) Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 5: 271-283 doi:10.1038/nri1589.
17. Yanaba K, Bouaziz J-D, Haas KM, Poe JC, Fujimoto M, et al.(2008) A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650 doi:10.1016/j.immuni.2008.03.017.
18. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM, (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944-950 doi:10.1038/ni833.
19. Gu H, Zou YR, Rajewsky K, (1993) Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell 73: 1155-1164.
20. Shreedhar VK, Pride MW, Sun Y, Kripke ML, Strickland FM, (1998) Origin and characteristics of ultraviolet-B radiation-induced suppressor T lymphocytes. J Immunol 161: 1327-1335.
21. Schwarz A, Beissert S, Grosse-Heitmeyer K, Gunzer M, Bluestone JA, et al.(2000) Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance. J Immunol 165: 1824-1831.
22. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WLG, et al.(2009) Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. Journal of Experimental Medicine 206: 1535-1547 doi:10.1084/jem.20082901.
23. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al.(2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
24. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, et al.(2007) Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 204: 1303-1310 doi:10.1084/jem.20062129.
25. Bopp T, Dehzad N, Reuter S, Klein M, Ullrich N, et al.(2009) Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. The Journal of Immunology 182: 4017-4024 doi:10.4049/jimmunol.0803310.
26. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, et al.(2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323.
27. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, et al.(2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275 doi:10.1126/science.1160062.
28. Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M, et al.(2002) CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med 196: 237-246.
29. Wang H, Peters T, Sindrilaru A, Kess D, Oreshkova T, et al.(2008) TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis. Journal of Clinical Investigation 118: 2629-2639 doi:10.1172/JCI34916.
30. Shi Y, Massagué J, (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
31. Worthington JJ, Klementowicz JE, Travis MA, (2011) TGFβ: a sleeping giant awoken by integrins. Trends Biochem Sci 36: 47-54 doi:10.1016/j.tibs.2010.08.002.
32. Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, et al.(2006) Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol 177: 7551-7558.
33. Rivas JM, Ullrich SE, (1992) Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 149: 3865-3871.
34. Chacón-Salinas R, Limón-Flores AY, Chávez-Blanco AD, Gonzalez-Estrada A, Ullrich SE, (2011) Mast cell-derived IL-10 suppresses germinal center formation by affecting T follicular helper cell function. J Immunol 186: 25-31 doi:10.4049/jimmunol.1001657.
35. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, et al.(2007) Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 204: 57-63 doi:10.1084/jem.20061852.
36. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W, (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
37. Bopp T, Palmetshofer A, Serfling E, Heib V, Schmitt S, et al.(2005) NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells. J Exp Med 201: 181-187 doi:10.1084/jem.20041538.